Table 1 - ATM inhibitors under preclinical and clinical investigation

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Structure | ATM IC50 (nM) | Status/Key findings |
| AZD1390 |  | 0.78 | Phase I clinical trial for brain cancer in combination with radiotherapy [16].  Phase I clinical trial for NSCLC in combination with radiotherapy [17]. Phase I clinical trial completed to assess brain PET imaging with 11C-labelled AZD1390 (labelled in the starred position) [5, 6]. |
| AZD0156 |  | 0.58 | Phase I clinical trial for advanced solid tumours, alone and in combination with other agents [18, 19]. |
| M4076 |  | 0.2 | Phase I clinical trial for advanced solid tumours [20, 21]. |
| M3541 |  | 0.5 | Completed phase I clinical trials for solid tumours in combination with radiotherapy [22]. |
| KU60019 |  | 6.3 | Preclinical *in vitro* evaluation of KU60019 in combination with CHK2 inhibitor, CX4945 [23, 24]. |
| KU55933 |  | 13 | First specific ATM inhibitor, demonstrated sensitisation of cells to ionising radiation and topoisomerase inhibitors [25]. |
| KU59403 |  | 3 | Preclinical investigation in combination with topoisomerase inhibitors and improved pharmacologic properties over previous KuDOS inhibitors [11]. |
| CP466722 |  | 410 | Demonstrated rapid and reversible inhibition of ATM *in vitro*, revealing that only transient ATM inhibition is require for cell sensitisation to ionising radiation [26, 27]. |